![Marc L. Lesnick](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc L. Lesnick
Fondatore presso Park Therapeutics, Inc.
Profilo
Marc L.
Lesnick is the founder of Park Therapeutics, Inc. Prior to this, he worked as Senior Vice President-Regulatory Affairs & Quality at Cascadian Therapeutics LLC, Senior Vice President-Regulatory Affairs at Shionogi, Inc., and Vice President-Regulatory Affairs & Quality at Spruce Biosciences, Inc. He holds a doctorate degree from the University of Oregon.
Posizioni attive di Marc L. Lesnick
Società | Posizione | Inizio |
---|---|---|
Park Therapeutics, Inc.
![]() Park Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Tris Pharma, Inc., Park Therapeutics, Inc. develops drugs for the treatment of pain. The company is based in Morristown, NJ. The company was founded by Marc L. Lesnick, James Hackworth. James Hackworth has been the CEO since incorporation. Park Therapeutics was acquired by Tris Pharma, Inc. on April 29, 2021. | Fondatore | - |
Precedenti posizioni note di Marc L. Lesnick
Società | Posizione | Fine |
---|---|---|
SPRUCE BIOSCIENCES, INC. | Consigliere Generale | - |
Shionogi, Inc.
![]() Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Consigliere Generale | - |
CASCADIAN THERAPEUTICS INC (USA) | Consigliere Generale | - |
Formazione di Marc L. Lesnick
University of Oregon | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
SPRUCE BIOSCIENCES, INC. | Health Technology |
Aziende private | 3 |
---|---|
Cascadian Therapeutics LLC
![]() Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC was a clinical-stage biopharmaceutical company, which focused on the development of therapeutic products for the treatment of cancer. Its product ONT-380, was an orally active and selective small-molecule HER2 inhibitor. The firm also developed preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on August 23, 1985 and was headquartered in Bothell, WA. | Health Technology |
Shionogi, Inc.
![]() Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Park Therapeutics, Inc.
![]() Park Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Tris Pharma, Inc., Park Therapeutics, Inc. develops drugs for the treatment of pain. The company is based in Morristown, NJ. The company was founded by Marc L. Lesnick, James Hackworth. James Hackworth has been the CEO since incorporation. Park Therapeutics was acquired by Tris Pharma, Inc. on April 29, 2021. | Health Technology |
- Borsa valori
- Insiders
- Marc L. Lesnick